Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: Mechanism-based inactivation of cytochrome P4503A by ritonavir

Drug Metabolism and Disposition

Volumn 26, Issue 6, 1998, Pages 552-561

  Koudriakova, Tatiana ^a   Iatsimirskaia, Eugenia ^b   Utkin, Ilya ^b   Gangl, Eric ^b   Vouros, Paul ^b   Storozhuk, Elena ^b   Orza, Daniela ^b   Marinina, Julia ^b   Gerber, Nicholas ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 ISOENZYME; INDINAVIR; PROTEINASE INHIBITOR; RITONAVIR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG TRANSFORMATION; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME KINETICS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; SMALL INTESTINE;

ANTI-HIV AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; INTESTINES; KETOCONAZOLE; KINETICS; MICROSOMES; MIXED FUNCTION OXYGENASES; RITONAVIR;

EID: 0031790709     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Balani SK, Woolf EJ, Hoagland VL, Sturgill MG, Deutsch PJ, Yeh KC and Lin JH (1996) Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans. Drug Metab Dispos 24:1389-1394.
2. Butler AM and Murray M (1997) Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation. J Pharmacol Exp Ther 280:966-973.
3. Chiba M, Hensleigh M and Lin JH (1997) Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Biochem Pharmacol 53:1187-1195.
4. Chiba M, Hensleigh M, Nishime JA, Balani SK and Lin JH (1996) Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab Dispos 24:307-314.
5. Chiba M, Nishime JA and Lin JH (1995) Potent and selective inactivation of human microsomal cytochrome P-450 isoforms by L-754,394, an investigational human immune deficiency virus protease inhibitor. J Pharmacol Exp Ther 275:1527-1534.
6. Crowley JR and Hollenberg PF (1995) Mechanism-based inactivation of rat liver cytochrome P4502B1 by phencyclidine and its oxidative product, the iminium ion. Drug Metab Dispos 23:786-793.
7. Darke PL, Nutt RF, Brady SF, Garsky VM, Ciccarone TM, Leu C-T, Lumma PK, Freidinger RM, Veber D and Sigal IS (1988) HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins Biochem Biophys Res Commun 156:297-303.
8. Denissen JF, Grabowski BA, Johnson MK, Buko AM, Kempf DJ, Thomas SB and Surber BW (1997) Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans. Drug Metab Dispos 25:489-501.
9. Fitzsimmons ME and Collins JM (1997) Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4. Drug Metab Dispos 25:256-266.
10. Gottlinger HG, Sodroski JG and Haseltine WA (1989) Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 86:5781-5785.
11. Gray MR and Tam YK (1991) Pharmacokinetics of drugs that inactivate metabolic enzymes. J Pharm Sci 80:121-127.
12. Guengerich FP (1990) Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chem Res Toxicol 3:363-371.
13. Hebert MF, Roberts JP, Prueksaritanont T and Benet LZ (1992) Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 52:453-457.
14. Houston JB (1994) Utility of in vitro drug metabolism data in prediction of in vivo metabolic clearance. Biochem Pharmacol 47:1469-1479.
15. Hsu A, Granneman R, Witt G, Locke C, Denissen J, Molla A, Valdes J, Smith J, Erdman K, Lyons N, Niu P, Decourt J-P, Fourtillan J-B, Girault J and Leonard JM (1997) Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 41:898-905.
16. Iatsimirskaia E, Tulebaev S, Storozhuk E, Utkin I, Smith D, Gerber N and Koudriakova T (1997) Metabolism of rifabutin in human enterocyte and liver microsomes: Kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents. Clin Pharmacol Ther 61:554-562.
17. Kempf DJ, Marsh KC, Denissen JF, McDonald E, Vasavanonda S, Flentge CA, Green BE, Fino L, Park CH, Kong X-P, Wideburg NE, Saldivar A, Ruiz L, Kati WM, Sham HL, Robins T, Stewart KD, Hsu A, Planner JJ, Leonard JM and Norbeck DW (1995) ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci USA 92:2484-2488.
18. Kempf DJ, Marsh KC, Kumar G, Rodrigues AD, Denissen JF, McDonald E, Kukulka MJ, Hsu A, Granneman GR, Baroldi PA, Sun E, Pizzuti D, Plattner JJ, Norbeck DW and Leonard JM (1997) Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 41:654-660.
19. Kolars JC, Schmiedlin-Ren P, Dobbins WO III, Schuetz J, Wrighton SA and Watkins PB (1992) Heterogeneity of cytochrome P450IIIA expression in rat gut epithelia. Gastroenterology 102:1186-1198.
20. Koudriakova T, Iatsimirskaia E, Tulebaev S, Spetie D, Utkin I, Mullet D, Thompson T, Vouros P and Gerber N (1996) In vivo disposition and metabolism by liver and enterocyte microsomes of the antitubercular drug rifabutin in rats. J Pharmacol Exp Ther 279:1300-1309.
21. Kraner JC, Morgan ET and Halpert JR (1994) Selective suppression of rat hepatic cytochrome P450 2C11 by chloramphenicol. J Pharmacol Exp Ther 270:1367-1372.
22. Kumar GN, Rodrigues AD, Buko AM and Denissen JF (1996) Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 277:423-431.
23. Lin JH, Chiba M, Balani SK, Chen I-W, Kwei GY-S, Vastag KJ and Nishime JA (1996) Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. Drug Metab Dispos 24:1111-1120.
24. Lin JH, Chiba M, Chen I-W, Vastag KJ, Nishime JA, Dorsey BD, Michelson SR and McDaniel SL (1995) Time- and dose-dependent pharmacokinetics of L-754,394, an HIV protease inhibitor, in rats, dogs and monkeys. J Pharmacol Exp Ther 274:264-269.
25. Lown KS, Kolars JC, Thummel KE, Barnett JK, Kunze KL, Wrighton SA and Watkins PB (1994) Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Drug Metab Dispos 22:947-952.
26. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
27. Mason EE, Printen KJ, Blommers TJ, Lewis JW and Scott DH (1980) Gastric bypass in morbid obesity. Am J Clin Nutr 33:395-405.
28. Mays DC, Hilliard JB, Wong DD, Chambers MA, Park SS, Gelboin HV and Gerber N (1990) Bioactivation of 8-methoxypsoralen and irreversible inactivation of cytochrome P-450 in mouse liver microsomes: modification by monoclonal antibodies, inhibition of drug metabolism and distribution of covalent adducts. J Pharmacol Exp Ther 254:720-731.
29. Merck & Co. (1996) Package insert for Crixivan (indinavir sulfate). Merck & Co., West Point, PA.
30. Pang KS and Rowland M (1977) Hepatic clearance of drugs. I. Theoretical consideration of a "well-stirred" model and a "parallel tube" model: influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular activity on hepatic drug clearance. J Pharmacokinet Biopham 5:625-653.
31. Roy AB (1972) Kinetic properties of arylsulphatase A: theoretical treatment. Biochim Biophys Acta 276:488-490.
32. Saton H, Gillette JR, Davies JW, Schulick RD and Pohl LR (1985) Immunochemical evidence of trifluoroacetylated cytochrome P450 in the liver of halothane-treated rats. Mol Pharmacol 28:468-474.
33. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD and Wilkinson GR (1996) Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 59:491-502.
34. Tinel M, Belghiti J, Descatoire V, Amouyal G, Letteron P, Geneve J, Larrey D and Pessayre D (1987) Inactivation of human liver cytochrome P-450 by the drug methoxsalen and other psoralen derivatives. Biochem Pharmacol 36:951-955.
35. Vacca JP, Dorsey BD, Schleif WA, Levin RB, McDaniel SL, Darke PL, Zugay J, Quintero JC. Blahy OM, Roth E, Sardana VV, Schlabach AJ, Graham PI, Condra JH, Gollib L, Holloway MK, Lin J, Chen I-W, Vastag K, Ostovic D, Anderson PS, Emini EA and Huff JR (1994) L-735,524: an orally bioavailable human immunodeficiency viras type 1 protease inhibitor. Proc Natl Acad Sci USA 91:4096-4100.
36. Watkins PB, Wrighton SA, Schuetz EG, Molowa DT and Guzelian PS (1987) Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 80:1029-1036.
37. Wilkinson GR (1987) Clearance approaches in pharmacology. Pharmacol Rev 39:1-42.